Compare RJF & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJF | ONC |
|---|---|---|
| Founded | 1962 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | RJF | ONC |
|---|---|---|
| Price | $162.68 | $331.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $181.00 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 1.1M | 319.7K |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 6.19 | N/A |
| EPS | ★ 10.30 | 0.58 |
| Revenue | ★ $14,015,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $13.65 | $36.37 |
| Revenue Next Year | $6.45 | $22.04 |
| P/E Ratio | ★ $15.79 | $566.55 |
| Revenue Growth | 9.52 | ★ 53.47 |
| 52 Week Low | $117.57 | $170.99 |
| 52 Week High | $177.66 | $385.22 |
| Indicator | RJF | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 46.47 |
| Support Level | $155.16 | $325.00 |
| Resistance Level | $157.68 | $345.58 |
| Average True Range (ATR) | 3.32 | 12.49 |
| MACD | 0.78 | -2.95 |
| Stochastic Oscillator | 94.78 | 14.07 |
Raymond James Financial is a diversified financial services firm that provides wealth management, investment banking, asset management, and capital markets services to individuals, corporations, and municipalities. The firm maintains an extensive catalogue of products and services across its business lines. However, the wealth management franchise generates the bulk of its revenues and earnings through a vast network of nearly 8,800 independent and employee-affiliated advisors, who collectively manage over $1.7 trillion in client assets as of fiscal year-end 2025. While Raymond James maintains a global footprint, the company derives over 90% of its revenue, and an even larger percentage of its operating income, from the United States.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.